Similarly, Smad3—a key downstream effector of TGF-β1 signaling—can be targeted using oligonucleotide inhibitors (e.g., SIS3) or small molecules to block profibrotic signals, as validated in liver fibrosis models (28). The gene discussed is SMAD3; the disease is Hepatic fibrosis.